The study examined fremanezumab in children and adolescents with episodic migraine, published in the New England Journal of Medicine (Volume 394, Issue 3, Pages 243-252, January 15, 2026). Fremanezumab is a monoclonal antibody that binds to the CGRP ligand and prevents inflammation around brain vessels, thereby reducing migraine attacks. In placebo-controlled studies in patients with episodic migraine (6-14 migraine days per month), there was a mean reduction in migraine days of 5.1-5.2 days with monthly dosing of 225 mg or quarterly dosing of 675 mg compared to placebo. Adverse effects were mostly mild, the most frequent reactions at the injection site (in 33% of patients), and did not lead to discontinuation of treatment. Fremanezumab showed low immunogenicity, antibodies did not reduce efficacy. Efficacy was maintained during long-term therapy for up to 12 months. The study confirmed safety and efficacy in children and adolescents, although not previously established.[1][2][3][4]